January 4, 2019
Novavax’ NanoFlu formulkation identified for the Phase 3 clinical trial and sale
Novavax reported Friday that the Phase 2 clinical trial found all formulations of NanoFlu were well-tolerated and elicited vigorous immune responses to the four strains included in the vaccine.